Abstract
Over the last decade, the number of health economic evaluations has increased substantially in the field of child psychiatry. The objective of the present paper is to offer an overview of economic evaluations of child psychiatric drug treatment. Major electronic databases, as well as abstract booklets from international clinical and health economics conferences with an external peer review process, were examined to search for comparative economic evaluations of child and adolescent psychiatric drug treatment. Most studies of pharmacotreatment were cost effectiveness analyses (CEAs) concerned with attention-deficit/hyperactivity disorder (ADHD). Three evaluations were done by or on behalf of agencies as part of ADHD-related health technology assessments. A number of economic studies used patient-level data from specific randomized clinical trials, especially the NIMH-initiated MTA (in childhood ADHD) and TADS (in adolescent major depression) studies. Almost all studies relied on narrow scale symptom scales to assess effects of treatment, even when quality-adjusted life years (QALYs) were reported. In many cases, effectiveness data came from short-term studies, and extrapolation to a one-year time horizon was usually based on assumptions. Even those evaluations attempting to address longer time horizons by way of modeling did not include the impact of treatment on long-term sequelae of the conditions studied, mainly due to a paucity of robust clinical data. Nevertheless, currently available health economic evaluations broadly suggest an acceptable to attractive cost effectiveness of medication management of ADHD, whereas there is no such evidence for child psychiatric disorders other than ADHD.
Keywords: Economic evaluation, cost effectiveness analysis, cost utility analysis, quality-adjusted life year (QALY), cost benefit analysis, health technology assessment, attention deficit hyperactivity disorder (ADHD), depression, pharmacoeconomics
Current Pharmaceutical Design
Title: The Pharmaceutical Economics of Child Psychiatric Drug Treatment
Volume: 16 Issue: 22
Author(s): Michael Schlander
Affiliation:
Keywords: Economic evaluation, cost effectiveness analysis, cost utility analysis, quality-adjusted life year (QALY), cost benefit analysis, health technology assessment, attention deficit hyperactivity disorder (ADHD), depression, pharmacoeconomics
Abstract: Over the last decade, the number of health economic evaluations has increased substantially in the field of child psychiatry. The objective of the present paper is to offer an overview of economic evaluations of child psychiatric drug treatment. Major electronic databases, as well as abstract booklets from international clinical and health economics conferences with an external peer review process, were examined to search for comparative economic evaluations of child and adolescent psychiatric drug treatment. Most studies of pharmacotreatment were cost effectiveness analyses (CEAs) concerned with attention-deficit/hyperactivity disorder (ADHD). Three evaluations were done by or on behalf of agencies as part of ADHD-related health technology assessments. A number of economic studies used patient-level data from specific randomized clinical trials, especially the NIMH-initiated MTA (in childhood ADHD) and TADS (in adolescent major depression) studies. Almost all studies relied on narrow scale symptom scales to assess effects of treatment, even when quality-adjusted life years (QALYs) were reported. In many cases, effectiveness data came from short-term studies, and extrapolation to a one-year time horizon was usually based on assumptions. Even those evaluations attempting to address longer time horizons by way of modeling did not include the impact of treatment on long-term sequelae of the conditions studied, mainly due to a paucity of robust clinical data. Nevertheless, currently available health economic evaluations broadly suggest an acceptable to attractive cost effectiveness of medication management of ADHD, whereas there is no such evidence for child psychiatric disorders other than ADHD.
Export Options
About this article
Cite this article as:
Schlander Michael, The Pharmaceutical Economics of Child Psychiatric Drug Treatment, Current Pharmaceutical Design 2010; 16 (22) . https://dx.doi.org/10.2174/138161210791959917
DOI https://dx.doi.org/10.2174/138161210791959917 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antibody Aggregate Removal by Hydroxyapatite Chromatography
Current Pharmaceutical Biotechnology Polyisoprenylated Cysteinyl Amide Inhibitors Deplete K-Ras and Induce Caspase-dependent Apoptosis in Lung Cancer Cells
Current Cancer Drug Targets 11C-verapamil to Assess P-gp Function in Human Brain During Aging,Depression and Neurodegenerative Disease
Current Topics in Medicinal Chemistry Synthetic Inhibitors of Group IVA and Group VIA Phospholipase A2
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Neurocognition in the Psychosis Risk Syndrome: A Quantitative and Qualitative Review
Current Pharmaceutical Design Ubisol-AquaTM: Coenzyme Q10 Prevents Antiretroviral Toxic Neuropathy in an In Vitro Model
Current HIV Research Targeted Therapies in Bone Sarcomas
Current Cancer Drug Targets Moraceae Plants with Tyrosinase Inhibitory Activity: A Review
Mini-Reviews in Medicinal Chemistry Histamine as an Anticonvulsant Inhibitory Neurotransmitter
Current Neuropharmacology The Management of Phosphodiesterase-5 (PDE5) Inhibitor Failure
Current Vascular Pharmacology Every Cloud Has a Silver Lining: Proneurogenic Effects of Aβ Oligomers and HMGB-1 via Activation of the RAGE-NF-κB Axis
CNS & Neurological Disorders - Drug Targets Aggressive Antioxidant Reductive Stress Impairs Brain Endothelial Cell Angiogenesis and Blood Brain Barrier Function
Current Neurovascular Research Structural Analysis of Relevant Drug Targets for Alzheimer's Disease: Novel Approaches to Drug Development
Current Bioactive Compounds Zoledronic Acid Use and Risk of Cognitive Decline among Elderly Women and Men with Osteoporosis
Endocrine, Metabolic & Immune Disorders - Drug Targets Biomarkers to Assess the Targeting of DNA Repair Pathways to Augment Tumor Response to Therapy
Current Molecular Medicine Inhibition of NF-kB Activation and Cytokines Production in THP-1 Monocytes by 2-Styrylchromones
Medicinal Chemistry Drug Development and PET-Diagnostics for Alzheimers Disease
Current Medicinal Chemistry Migration and Function of Th17 Cells
Inflammation & Allergy - Drug Targets (Discontinued) Single Heterocyclic Compounds as Monoamine Oxidase Inhibitors: From Past to Present
Mini-Reviews in Medicinal Chemistry Overview of the Recent Advances in Pathophysiology and Treatment for Autism
CNS & Neurological Disorders - Drug Targets